Glaxo Wellcome Inc.

Smithkline Beecham Corporation

Glaxosmithkline LLC

Jeffrey Alan Oplinger

Eric Steven Furfine

Barry George Shearer

Edward Patrick Garvey

Jon Loren Collins

Timothy Mark Willson

Eric C Bigham

Michael H Rabinowitz

Philip Stewart Turnbull

David John Cowan

Milana Dezube

Eric Eugene Boros

Anthony Louis Handlon

Clifton Earl Hyman

James Mood Chapman, Jr

Peter Jonathan Brown

Ludwig William Stuart

Ashok Bhandari

Zhengdong Wu

The present invention relates to novel fused heterocyclic ring system compounds and methods for their use in the treatment and prevention of diseases or conditions.

Condensed heterocyclic compounds as calcitonin agonists

The present invention discloses compounds of formula (I), and tautomeric forms, pharmaceutically acceptable salts, or solvates thereof. Preferably, the compounds of the invention are dual activators of hPPAR&ggr; and hPPAR{acute over (&agr;)}.

Substituted oxazoles and thiazoles derivatives as hPPAR&ggr; and hPPAR&agr; activators

A class of acetamidine derivatives of general formula (I)

Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase

Novel compounds of Formula (1) and esters, salts, and physiologically functional derivatives thereof are disclosed. Methods for preparing and using the compounds are also disclosed. Many of these compounds are selective activators of PPAR alpha. The compounds are particularly useful for treating obesity.

Chemical compounds

The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerbral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

Substituted urea and isothiourea derivatives as no synthase inhibitors

The use of an N-substituted urea derivative for the manufacture of a medicament for the treatment of a condition where there is an advantage in inhibiting the NO synthase enzyme, in particular cerebral ischemia, and pharmaceutical formulations therefor are disclosed. Novel N-substituted urea derivatives and processes for the preparation thereof are also described.

Substituted urea and isothiorea derivatives as no synthase inhibitors

Acetamidine derivatives and their use as inhibitors for the nitric oxide

Growing community of inventors

Durham, NC, United States of America

Jeffrey Alan Oplinger